. Here we identify novel non-coding genetic variants with large effects on BMD (n total 5 53,236) and fracture (n total 5 508,253) in individuals of European ancestry from the general population. Associations for BMD were derived from whole-genome sequencing (n 5 2,882 from UK10K (ref. 10); a population-based genome sequencing consortium), whole-exome sequencing (n 5 3,549), deep imputation of genotyped samples using a combined UK10K/1000 Genomes reference panel (n 5 26,534), and de novo replication genotyping (n 5 20,271). We identified a low-frequency non-coding variant near a novel locus, EN1, with an effect size fourfold larger than the mean of previously reported common variants for lumbar spine BMD 8 (rs11692564(T), MAF 5 1.6%, replication effect size 5 10.20 s.d., P meta 5 2 3 10 214 ), which was also associated with a decreased risk of fracture (odds ratio 5 0.85; P 5 2 3 10
211
; n cases 5 98,742 and n controls 5 409,511). Using an En1 cre/flox mouse model, we observed that conditional loss of En1 results in low bone mass, probably as a consequence of high bone turnover. We also identified a novel lowfrequency non-coding variant with large effects on BMD near WNT16 (rs148771817(T), MAF 5 1.2%, replication effect size 5 10.41 s.d., P meta 5 1 3 10
). In general, there was an excess of association signals arising from deleterious coding and conserved non-coding variants. These findings provide evidence that low-frequency non-coding variants have large effects on BMD and fracture, thereby providing rationale for whole-genome sequencing and improved imputation reference panels to study the genetic architecture of complex traits and disease in the general population.
Recently, genetic discoveries have generally focused on common variants of small effect and rare coding variants identified through genome-wide association studies (GWAS) and whole-exome sequencing initiatives, respectively 11, 12 . The effect of low-frequency and rare non-coding variants upon common diseases, and their underlying traits has been recently explored in an isolated population 13, 14 , but has not been well-studied to date in the general population. The UK10K project has generated a large whole-genome sequence-based resource to address this question in a general European-ancestry population 10 , which is tenfold larger than the European subset of the 1000 Genomes project reference 15 . Osteoporosis, diagnosed mainly through measurement of bone mineral density (BMD), is a common systemic skeletal disease characterized by an increased propensity to fracture. The narrow-sense heritability of BMD has been estimated to be ,85%, and GWAS have successfully identified numerous loci associated with BMD which in total explain ,5% of the genetic variance for this trait 16 . However, these studies have been mainly unable to assess the role of low frequency (MAF 1-5%) and rare (MAF # 1%) genetic variation, as these methods rely on testing common variants (MAF $ 5%). A recent sequencing-based study identified a rare nonsense variant associated with BMD using 4,931 Icelandic subjects with low BMD and 69,034 population-based controls 9 . This coding variant, which disrupts the function of LGR4, appears to be confined to the Icelandic population. 119,000,000 119,500,000 120,000,000 DBI   TMEM37   SCTR   PCDP1   rs75336963  rs79070542  rs6724673  rs6542457   rs148285156  rs115242848  rs141795717   rs11692564   rs144279715  rs147372226  rs192727592  rs11675517  rs192508258  rs144832051  rs188303909  rs140902470 11960 11940 11930 11920 Figure 1 | Association signals near engrailed homeobox-1 for lumbar spine BMD. a, A topological domain includes associated variants and EN1, and chromatin interaction analysis with paired-end tag sequencing (ChIA-PET for CTCF in MCF-7 cell line) suggests a smaller interacting region containing EN1, and three genome-wide significant variants for lumbar spine BMD (in red). hES cell, human embryonic stem cell. b, Association signals at the EN1 locus (green line at P 5 1.2 3 10 28 ) for lumbar spine BMD. Red circles and triangles represent results from discovery and combined discovery and replication using fixed-effects meta-analysis (see Supplementary Information), respectively. c, Allele frequency versus absolute effect size for lumbar spine BMD for previously identified variants (blue) 8 and the three EN1 novel variants (red). The red line denotes the mean of previously reported effect sizes.
To investigate the role of rare and low-frequency genetic variation on BMD in the general population of European descent, we first undertook whole-genome sequencing in 2,882 subjects from two cohorts in the UK10K project and whole-exome sequencing in 3,549 subjects from five cohorts (Supplementary Table 1 ) with BMD phenotypes. We then used a novel imputation reference panel generated by the UK10K and 1000 Genomes consortia to impute variants that were missing, or poorly captured, from previous GWAS studies in 26,534 subjects (Supplementary Table 1 and Extended Data Fig. 1a ). The combined UK10K and 1000 Genomes reference panel, which contained 3,781 and 379 European individuals with whole-genome sequences from UK10K and 1000 Genomes projects, respectively, enabled improved imputation, particularly of lowfrequency variants, when compared to the 1000 Genomes reference panel alone 17 . We then undertook de novo replication genotyping of lead variants in 13 cohorts for BMD, comprising 20,271 individuals of European descent.
We meta-analyzed association results from all discovery cohorts (n total 5 32,965, Supplementary Table 1) for BMD measured at the forearm, femoral neck and lumbar spine, the sites where osteoporotic fractures are most prevalent. We tested bi-allelic single nucleotide variants (SNVs) with MAF $ 0.5% for association, declaring genome-wide statistical significance at P # 1.2 3 10 28 (accounting for all independent SNVs above this MAF threshold; Supplementary Methods) 18 . The sequence kernel association test (SKAT) was used to assess association of regions containing SNVs with MAF # 5% and #1% (Supplementary Methods). All summary-level meta-analytic results are available for unrestricted download (http://www.gefos.org). Novel genome-wide significant loci were then tested for their relationship with fracture in up to 508,253 individuals. Finally, functional genomics as well as cellular and animal models were used to investigate the relevance of these novel genetic associations to bone physiology.
Through meta-analysis of sequenced and imputed single-SNV association tests from the discovery cohorts (Supplementary Table 1) , we identified a novel locus at 2q14.2 harbouring variants associated with lumbar spine BMD (lead low-frequency SNV rs11692564(T), MAF 5 1.7%, effect size 5 10.24 s.d., P 5 4 3 10
29
, Fig. 1 and Table 1 ). The direction of effect was consistent across all discovery cohorts (Extended Data Fig. 2 ) and the mean imputation information score for the imputed cohorts was 0.71 (Supplementary Table 2 ). This variant is located 53 kilobase pairs (kb) downstream from engrailed homeobox-1 (EN1), which, to our knowledge, has not previously been associated with any osteoporosis-related traits in humans. The rs11692564 variant was not present on HapMap imputation panels, nor on genotyping chips, underlining the importance of developing more comprehensive imputation reference panels.
To validate whole-genome sequencing genotypes at rs11692564, we genotyped 1,853 whole-genome sequenced subjects, and found all genotypes to be perfectly concordant (Supplementary Table 3 ). We validated imputation of rs11692564 in 3,601 imputed subjects through direct genotyping and observed that the association strengthened, and its statistical significance improved, as compared to imputed results (lumbar spine: imputed effect size 5 0.22 s. ). Meta-analysis of the discovery and replication cohorts provided strong evidence for association (P combined-meta 5 2 3 10 214 ) ( Table 1) . We also identified an additional association signal, arising from rs55983207 (MAF 5 4%), 17 kb downstream of rs11692564 (r 2 5 0.001) to be associated with femoral neck BMD from the combined meta-analysis (P meta 5 7.2 3 10 215 , Table 1 ). A haplotype containing both effect alleles was not observed from within the UK10K wholegenome sequenced cohort (total number of haplotypes 5 7,562).
In addition to rs11692564, we also observed two additional novel genome-wide significant variants for lumbar spine BMD near EN1, rs6542457 (MAF 5 5.8%) and rs188303909 (MAF 5 1.6%), which are 391 kb downstream and 67 kb upstream from rs11692564, respectively ( Fig. 1b and Table 1 ). Variant rs188303909 was in moderate linkage disequilibrium (LD) with rs11692564 (r 2 5 0.47), and conditional analysis demonstrated that these two association signals were not independent (Supplementary Table 5 ). However, rs6542457 was in low LD with rs11692564 (r 2 5 0.002), and remained independent in conditional analyses (Supplementary Table 5 ). Overall, the EN1 locus harbours multiple non-coding variants associated with lumbar spine 
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and a single variant associated with femoral neck BMD. All three genome-wide significant variants for lumbar spine BMD (Table 1) co-localize solely with EN1 in a sub-region of high interaction frequency within a single topologically associated domain 19 (Fig. 1a) . The mean effect size of previously reported genome-wide significant single nucleotide polymorphisms (SNPs) (MAF $ 5%) from the largest GWAS meta-analysis to date for lumbar spine and femoral BMD was 0.048 s.d. and the largest effect size was 0.1 s.d.
8
. Hence, the observed effect size at rs11692564 is fourfold larger than this mean and twice that of the largest previously reported effect (Fig. 1c) 
. For all genome-wide significant variants, we observed larger effect sizes across decreasing MAF bins (Fig. 2a ).
An increase in BMD is associated with a decrease in risk of bone fracture. We therefore tested the association of rs11692564(T) (the low-frequency allele at EN1 associated with the largest increase in BMD) in 18 cohorts comprising 508,253 individuals (98,742 cases and 409,511 controls, Supplementary Table 6 ). rs11692564(T) was strongly associated with a decreased risk of fracture (odds ratio (OR) 5 0.85 (95% confidence interval (CI): 0.80-0.89); P 5 2.0 3 10
211
; I 2 5 0.00) ( Table 2 and Supplementary Table 7 ). Table 2 also shows clear associations between other variants near EN1 and risk of fracture. The fracture association at rs11692564 was 2.9-fold larger than the mean of fracture associations detected in the largest GWAS to date, and 2.0-fold larger than the largest previously identified fracture association 8 . . Investigating the functional role of EN1, we detected En1 expression during osteoblastogenesis in developing and mature cultured murine calvarial osteoblasts, but not in marrow-derived osteoclasts, or in human primary osteoclast cultures ( Fig. 3a and Extended Data Fig. 3 ). To determine where En1 is active in adult bones, we analysed vertebrae from En1 lacZ/1 knock-in mice 23 and detected LacZ expression in proliferative and hypertrophic chondrocytes, osteogenic cells in the periosteum and trabecular bone surface, and in osteocytes of cortical and trabecular bone ( Fig. 3b and Extended Data Fig. 4) .
Using En1 cre/1
; R26 lox-STOP-lox-EYFP reporter mice to genetically tag cells for which the En1 promoter was active at any point within a cell , n 5 6). By micro-CT, sdEn1 mutants exhibit decreased L5 trabecular number (Tb.N) and thickness (Tb.Th), as well as deceased bone volume fraction (BV/TV). Using histomorphometry, sdEn1 mutants exhibit increased osteoclastic area (TRAP/BS). BS, bone surface; TRAP, tartrate acid staining. Average for each measure denoted by the solid horizontal line. For each group, P value between control and sdEn1 is noted below label and was computed using paired t-test. Data Fig. 4) . As most En1 2/2 animals die soon after birth, we generated En1 cre/flox self-deleted En1 (sdEn1) conditional mutants 24 (n 5 5) and demonstrated by X-ray microcomputed tomography (micro-CT) that mutants have lower trabecular bone volume fraction (BV/TV), trabecular number, and trabecular thickness in both the lumbar L5 vertebrae (Fig. 3c, d and Extended Data Fig. 5 ) and the femur (Extended Data Fig. 5 ) as compared to littermate controls (n 5 6). A decrease in femoral cortical thickness was also observed (Extended Data Fig. 5 ). By histomorphometry (Fig. 3c) , we observed that the sdEn1 mice had a statistically higher proportion of osteogenic and osteoclastic cells compared to littermate controls ( Fig. 3d and Supplementary Table 8) . The driving force for the low bone mass would appear to be an increase in osteoclastic activity induced by En1 null osteogenic cells. This in turn initiates the expected coupled increase in mineralizing bone formation (Fig. 3b, d ) mediated by an increased number of osteogenic cells and thus conforms to a high turnover osteoporosis-like phenotype, although dynamic histomorphometry and evidence from bone turn-over markers would be required to confirm an increased rate of bone formation (Extended Data Fig. 4 ). Genetic evidence from homologous regions in mice also supported a role for En1 in bone, as the homologous region contained a quantitative trait loci (QTL) peak for femur BMD (Supplementary Table 9) 25 . These findings, together with an earlier study focusing on En1 function in calvarial bone development 22 implicate this gene as an important mediator in skeletal biology.
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Together, these findings suggest that EN1 plays an important role in bone physiology and that low-frequency non-coding variants mapping near EN1 have large effects on BMD and risk of fracture in the general European population.
We also identified a novel SNV at 7q31.31 within the intron of CPED1 (rs148771817(T), MAF 5 1.2%, effect size 5 10.47 s.d., P discovery 5 9.31 3 10
29
) associated with forearm BMD (Table 1,  Supplementary Table 10 and Extended Data Fig. 6 ). We replicated the association at rs148771817 in 2,539 independent individuals and found a similar effect size (effect size 5 10.41 s.d., P 5 6 3 10 24 ), and combined meta-analysis of the discovery and replication cohorts for further improved statistical evidence for association (10.46 s.d., P 5 1 3 10 211 ) ( Table 1) . This variant had an effect size 2.2-fold larger than the mean of previously reported effects for common variants associated with forearm BMD (Extended Data Fig. 6) 
26
. We previously identified rs7776725 to be associated with BMD at WNT16, a gene neighbouring CPED1, (Extended Data Fig. 6 ) and demonstrated that knockout of Wnt16 in mice confers a 50% decrease in bone strength (P 5 7 3 10 213 ) 26, 27 . We have recently shown that osteoblast-derived Wnt16 represses osteoclastogenesis 28 .
27
; Extended Data Fig. 6d) . Similarly, conditional analysis of the common variant upon rs148771817 revealed little change in the effect size or the statistical significance (Supplementary Table 5 ). Although we acknowledge that both variants may be causal, our data does not permit us to distinguish if one or both of these variants have distinct biologic effects.
While rs148771817 is intronic in CPED1, we found that DNA accessibility at this region, as measured by DNase I hypersensitivity data from ENCODE studies, was moderately correlated with DNA accessibility at the WNT16 promoter in 305 cell types (maximum r 2 5 0.4, P 5 2.2 3 10 215 , Supplementary Table 11), whereas correlation to the promoter of CPED1 was lower (maximum r 2 5 0.1, P 5 0.06). Moreover, analysis of chromosome conformation capture Hi-C interaction frequencies from human H1 embryonic stem cells shows elevated interaction frequency between rs148771817 and WNT16 (Extended Data Fig. 6 ), though we also observed stronger interactions between these loci and their immediate neighbouring regions.
We assessed whether association signals were enriched for deleterious coding SNVs or SNVs with increased evolutionary constraint (see Supplementary Methods). These two groups of SNVs were matched to control SNVs by MAF and distance to gene (Supplementary Methods  and Supplementary Table 12) , followed by LD pruning (r 2 , 0.2). We observed enrichment of association signal across the spectrum of positive evolutionary constraint thresholds, which was comparable to deleterious coding variants (Fig. 2b) .
In total, we have identified multiple variants associated with BMD, including 3 genome-wide significant loci for forearm BMD, 14 for femoral neck and 19 for lumbar spine (Supplementary Tables 10,  13 -15, and Extended Data Figs 7 and 8) . A common variant not on previous HapMap imputation panels, near the SOX6 gene was also identified (rs11024028, MAF 5 20%) (Table 1) , and was found to be an independent signal from a previously reported signal at this locus (rs7108738, r 2 5 0.002) 8 . Consistent with recent experiments 29, 30 , region-based collapsing methods did not identify any convincing novel associations that were not already identified as genome-wide significant through single SNV associations. This included collapsing variants below 1% and 5% MAF thresholds, including all variants, only variants with increased GERP11 scores or those from protein-coding regions (Supplementary Table 16 and Extended Data Figs 9 and 10).
We have identified low-frequency, non-coding genetic variants of large effect that are present in the general population and associate with BMD and fracture. These variants have effect sizes up to fourfold larger than the mean effect described for common variants associated with BMD and approximately threefold larger than those for fracture. Our study illustrates that larger reference panels, covering relevant ethnicities, will facilitate the discovery of low frequency and rare variants. This was enabled here by a large imputation reference panel (UK10K and 1000 Genomes) which offered tenfold more European samples than the 1000 Genomes reference panel available at the time of analysis (phase I version 3). Although we did not identify coding lowfrequency or rare variants associated with BMD at a genome-wide significant level, we did observe that deleterious coding variants were enriched for association as a group. This suggests the existence of as yet undiscovered coding variants influencing BMD. Importantly, we have also generated new functional evidence for a central role of the homeobox protein engrailed-1 gene in regulation of BMD and identified EN1 as a critical protein in bone biology. Our findings demonstrate the utility of whole-genome sequencing-based discovery and deep imputation to enable the identification of novel genetic associations. These discoveries provide an improved understanding of the pathophysiology of osteoporosis and suggest that more comprehensive sets of whole-genome sequenced individuals, covering relevant ethnicities, will enable accurate imputation and thus facilitate discovery of low frequency and rare variants influencing complex traits and common disease.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. . SNV calls were completed using samtools/bcftools and VQSR and GATK were used to recall these calls. Whole-exome sequencing. The AOGC, FHS, RS-I, ESP and ERF cohorts were whole-exome sequenced as described in the Supplementary Information. Whole-genome genotyping. All remaining discovery cohorts were genome-wide genotyped and imputed to the UK10K/1000 Genomes reference panel, as described in the Supplementary Information. Association testing for BMD. Single variants with a MAF . 0.5% were tested for an additive effect on lumbar spine, femoral neck and forearm BMD, adjusting for sex, age, age 2 , weight and standardized to have a mean of zero and a standard deviation of one. Meta-analysis of cohort-level summary statistics was undertaken using GWAMA 32 . Conditional analyses for significant SNVs was performed using GCTA 33 . Region-based collapsing tests were performed using skatMeta 34 , an implementation of the SKAT method 35 that enables the meta-analysis of multiple cohorts. For each cohort, variants with MAF # 5% or #1% were collected and meta-analysis using skatMeta was conducted for windows of 30 SNVs within each region, overlapping by 10 SNVs. Replication genotyping. Lead SNVs were selected for replication genotyping, which was performed at LGC Genomics, Erasmus MC and deCODE Genetics using KASP genotyping. Association testing for replication genotyping was undertaken using the same additive model, using the same covariates for BMD, as above. Fracture association testing. Fractures were defined as those occurring at any site, except fingers, toes and skull, after age 18. Both incident and prevalent fractures were included and were verified by either radiographic, casting, physician, or subject reporting. Fractures resulting from any type of trauma were considered. Covariates included in the additive model were age, age 2 , sex, height, weight, oestogen/menopause status (when available), ancestral genetic background and cohort-specific covariates (such as clinical centre). Association testing was done in two phases. The first involved all 1,482 genome-wide significant SNVs for BMD. In the second phase of fracture association testing, variants at EN1 were assessed in 18 cohorts, comprising 98,467 cases and 409,736 controls. Meta-analysis of cohort-level summary statistics was performed using GWAMA 32 .
Functional genomics. We tested whether variants with increasing GERP11 scores 36 were more strongly associated with BMD than SNVs matched for distance to gene and MAF, after LD pruning using PLINK 37 at an r 2 of ,0.2, using windows of 100 kb and a step of 20 kb. Coding variants were partitioned as deleterious using Variant Effect Predictor 38 LD pruned (r 2 , 0.2). The proportion of variants passing an FDR q-value of #0.05 were reported. En1 murine expression experiments. Pre-osteoblast-like cell were differentiated to osteoblasts from calvaria of C57BL/6J mice and expression levels of each gene was quantified using RNA-seq. The temporal expression of En1 in cell culture experiments of these osteoblasts and bone-marrow-derived osteoclasts (isolated from long bones of six-week-old mice) was measured by PCR, with Bglap (osteocalcin) and Tnfrsf11a (RANK), serving as controls. Total mRNA for En1 in osteoblasts was quantified using real-time PCR. Micro-CT and histomorphometry. Mouse husbandry and all experiments were performed in accordance with Memorial Sloan-Kettering Cancer Center Institutional Animal Care and Use Committee-approved protocols. Bone characteristics of self-deleted conditional En1(sdEn1) mutants were compared to En1 1/flox littermates using micro-CT. The same animals were assessed for histomorphometry (and laboratories performing micro-CT and histomorphometry were blinded to each other's results). After tissue sectioning, samples were stained for calcification (calcein blue), tartrate acid (TRAP) to assess for osteoclasts and alkaline phosphatase to assess for osteoblasts. Murine histology. Two-month-old En1 lacZ/1 mice 39 were sectioned at bone sites and stained for X-gal and/or alkaline phosphatase and imaged at 3400. a, Quantification of Dock8 expression and its temporal pattern through RNAseq in cultured calvarial murine osteoblasts across day 2 through to day 18 of osteoblast development. Shown for comparison is Bglap, which encodes osteocalcin, a critical protein in osteoblasts. b, Quantification of expression of genome-wide significant genes and their temporal pattern through RNA-seq in cultured calvarial murine osteoblasts across day 2 through to day 18 of osteoblast development. c, Expression of EN1 mRNA in human cells presented as per cent of GAPDH mRNA. d, Expression of En1 in control and sdEn1 mice in purified osteoblast culture. For osteoblast marker gene expression, total mRNAs were purified from osteoblast cultures at day 10 and measured using quantitative real-time PCR. mRNA levels were normalized relative to GAPDH mRNA. e. Real-time PCR expression of control and sdEn1 as compared to 18S mRNA in whole vertebral bone extract. All data are shown as mean 6 s.e.m. Significance computed by Student's unpaired t-test. , respectively). The novel genome-wide significant SNV, rs148771817, within an intron of CPED1, and the lead genome-wide significant SNV rs7776725 upstream to WNT16 (within FAM3C) are in low LD with each other. c, Allele frequency versus absolute effect size (in standard deviations) for forearm BMD of all previously identified genome-wide significant variants (blue) 8 and the novel variant within CPED1 (red), rs148771817 from replication meta-analysis. The blue line denotes the mean of effect sizes for previously reported forearm BMD variants. d, Meta-analysis summary statistics of rs148771817 conditioned on rs7776725. 
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Extended Data Figure 10 | Single variant analysis of signals from regionbased tests. a, Drop-one SNV (left) and drop-one cohort (right) for genomewide significant 30 SNV windows for femoral neck and forearm BMD from skatMeta analysis. On left, for a given 30 SNV window, the 2log 10 P of skatMeta test for 29 SNVs, excluding (that is, dropping) the SNV at position labelled on the x axis. On right, for given 30 SNV window on left, the 2log 10 P of skatMeta test for all cohorts, excluding (that is, dropping) cohort labelled on x axis. b, Regional view of CPED1/WNT16 locus for forearm BMD. Significant SNVs from single variant meta-analysis (rs148771817 and rs79162867, in blue) overlap significant regions found using region-based test (red bars).
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